<![CDATA[FDA Traditionally Approves Selpercatinib in RET+ Solid Tumors]]>
RegulatoryapprovedselpercatinibPositive
AI Analysis
Summary
FDA granted traditional approval of selpercatinib for RET gene fusion-positive solid tumors, supported by efficacy findings from phase 1/2 LIBRETTO-001 and LIBRETTO-021 trials.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Met
Outcome Details
FDA traditional approval in RET+ solid tumors
Importance:8/10
Sentiment:
0.85
FDA approvalRET fusion-positivesolid tumorsLIBRETTO-001LIBRETTO-021
Related Companies
Read the original article
Published by Cancer Network on July 14, 2026 6:21 PM